Results 121 to 130 of about 1,866 (169)

New drug: Bimekizumab for plaque psoriasis

Australian Prescriber, 2022
openaire   +3 more sources

Bimekizumab Efficacy by Patient Subgroups in Moderate to Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results from BE HEARD EXT

Introduction Response to hidradenitis suppurativa (HS) treatment can vary depending on patient characteristics, necessitating new treatments with consistent efficacy.1 Bimekizumab is a humanized IgG1 monoclonal antibody that inhibits interleukin (IL)-17F
Alejandro Molina-Leyva, Georgios Kokolakis, Evelina Van Ree, Christina Crater, Christopher J. Sayed, Yosuke Ishitsuka, Tom Vaux, Martina L. Porter, Jacek C. Szepietowski   +8 more
core   +1 more source

Bimekizumab in refractory pityriasis rubra pilaris

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2023
Christian Kromer, Michael P. Schön, Rotraut Mössner   +2 more
openaire   +3 more sources

Bimekizumab: The First FDA-Approved Dual IL-17A/IL-17F Inhibitor for Plaque Psoriasis – A Comprehensive Literature Review

Psoriasis: Targets and Therapy
Sukainah Ahmed Al Alshaikh, Zahra Mohammad Almarhoon, Hisham Momattin, Mahdi Aleid, Zahra H Almousa, Ali Kamal Alqaisum, Fatimah Ismail Mobarki, Sarah Aon Almakki, Hamzah Alturfi, Kouther Jamil Almajed Department of Pharmacy, Mouwasat Hospital, Dammam ...
Al Alshaikh SA, Almarhoon ZM, Momattin H, Aleid M, Almousa ZH, Alqaisum AK, Mobarki FI, Almakki SA, Alturfi H, Almajed KJ   +9 more
doaj  

Real‐World Experience Using Bimekizumab in a Patient Cohort With Plaque‐Type Psoriasis and Chronic Kidney Disease: A 48‐Week Retrospective Multicentre Study

International Journal of Dermatology
Z. Fratton, A. Balato, S. Bighetti, L. Bettolini, V. Maione, P. Calzavara-Pinton, D. Buononato, G. Stinco, E. Errichetti   +8 more
semanticscholar   +1 more source

Real-life Experience of Bimekizumab in 27 Obese Patients with Plaque-type Psoriasis: A 24-week Multicenter Retrospective Study

Dermatology Practical & Conceptual
Z. Fratton, V. Maione, S. Bighetti, L. Bettolini, G. Stinco, E. Errichetti   +5 more
semanticscholar   +1 more source

Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation—IL PSO (Italian Landscape Psoriasis)

Clinical drug investigation
M. Esposito, P. Gisondi, C. Assorgi, F. Bellinato, P. Brianti, M. Burlando, Giovanna Brunasso, S. Caccavale, G. Caldarola, E. Campione, P. G. Calzavara Pinton, A. Campanati, C. Carrera, A. Carugno, E. Cozzani, Antonio Costanzo, F. Cusano, P. Dapavo, A. Dattola, C. De Simone, R. Di Caprio, F. Diotallevi, M. Fargnoli, F. Gaiani, A. Giunta, P. Malagoli, A. Marzano, M. Megna, S. Mercuri, E. Mortato, A. Narcisi, D. Orsini, L. Potestio, P. Quaglino, A. Richetta, F. Romano, P. Sena, E. Vagnozzi, M. Venturini, F. Loconsole, A. Balato   +40 more
semanticscholar   +1 more source

Bimekizumab for recalcitrant pyoderma gangrenosum

JAAD Case Reports
Christina Tolete, Adam Friedman, Joaquin Calderon, Leonardo Tjahjono   +3 more
openaire   +3 more sources

Bimekizumab for Psoriasis: Raising the Bar in Treatment

International Journal of Dermatology
openaire   +2 more sources

Bimekizumab Versus Secukinumab in Plaque Psoriasis

New England Journal of Medicine, 2021
BACKGROUND Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively inhibits interleukin-17A alone, in patients ...
Kristian Reich, Melinda Gooderham
exaly   +5 more sources